Thrombotic Thrombocytopenic Purpura

Studies from University of Paris provide new data on lupus

Thrombotic Thrombocytopenic Purpura Library Library Home This article was published in Biotech Business Week, which you can subscribe to online.

"Nonetheless, they remain relevant for some selected patients with life-threatening manifestations and/or severe therapy-resistant manifestations. They can be used as an adjuvant therapy in combination with corticosteroids and, when required, other immunosuppressant(s) for refractory renal disease, alveolar hemorrhage, some neuropsychiatric manifestations, thrombotic thrombocytopenic purpura, catastrophic antiphospholipid syndrome, hyperviscosity syndrome or symptomatic cryoglobulinemia," wrote C. Pagnoux and colleagues, University of Paris.

The researchers concluded: "The use of newer technologies, like immunoadsorption, possibly in combination with recent biologics, might, in the future, offer some new perspectives for extracorporeal therapy of systemic lupus erythematosus."

Pagnoux and colleagues published their study in Transfusion and Apheresis Science (Plasma exchange for systemic lupus erythematosus. Transfusion and Apheresis Science, 2007;36(2):187-193).

For additional information, contact C. Pagnoux, University of Paris, Dept. of Internal Medical, Hopital Cochin, Assistance Public Hopital Paris, 27 Rue Faubourg, F-75689 Paris 14, France.

The publisher's contact information for the journal Transfusion and Apheresis Science is: Pergamon-Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England.

Keywords: France, Paris, Biologics, Biotechnology, Blood Transfusion, Clinical Trial Research, Clinical Trials, Medical Device, Nephritis, Post-Trials Research, Syndrome, Systemic Lupus Erythematosus, Transfusion Medicine, University of Paris.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.